Sunday, November 18, 2018 12:30:05 PM
The first section, Getting Ready, contains, what has to be, 2 important IPIX goals:
1. To raise (non-dilutive) cash.
2. Validation.
The second section, Defining Wants and needs, 1st bullet point,
"Do you need money immediately or does it make more sense to maximize royalties later?"
I believe this bullet point factors into Leo's bargaining strategy. IPIX, obviously, needs cash now and Bertolino has stated IPIX's objective of maximizing value.
My understanding is that Leo first attempted to strike a deal for B-OM only and that it was the BP who was responsible for the addition of IBD to the deal (term sheet). This indicates to me that Leo recognizes that IPIX's weak financial position will probably lead to a deal that's more favorable to the front-end than the back-end.
I believe Leo has wisely decided that IPIX's financial condition warrants cutting a deal on an indication or two. IMO, Leo is not about to negotiate away the long-term, highly-valuable Brilacidin platform in an atmosphere that is favorable to a front-end loaded agreement. I believe this would be consistent with the IPIX stated goal of maximizing value.
https://cdn.ymaws.com/www.michbio.org/resource/resmgr/BioToolBox_-_BioResearch/Biotech-Licensing-Negotiatio.pdf
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM